<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9870">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978456</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2016-24</org_study_id>
    <nct_id>NCT02978456</nct_id>
  </id_info>
  <brief_title>Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation</brief_title>
  <acronym>GUIDE DES</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare clinical outcomes between quantitative coronary
      angiography -guided and Intravascular ultrasound -guided strategy in patients with
      significant coronary artery disease undergoing Drug eluting stent implantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12 months</time_frame>
    <description>the cumulative incidence of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 12 months after the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>24 hours</time_frame>
    <description>Achievement of final stent residual stenosis of less than 30% by QCA with successful deployment of at least one stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (24 hour after an index procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (cardiac, vascular, non-cardiovascular)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (definite/probable)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic analysis</measure>
    <time_frame>12 months</time_frame>
    <description>cost-effectiveness of QCA- versus IVUS-guided DES implantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1528</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenoses</condition>
  <arm_group>
    <arm_group_label>quantitative coronary angiography guided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravascular ultrasound guided</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>quantitative coronary angiography guided coronary intervention with drug-eluting stent</intervention_name>
    <arm_group_label>quantitative coronary angiography guided</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intravascular ultrasound guided coronary intervention with drug-eluting stent</intervention_name>
    <arm_group_label>Intravascular ultrasound guided</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 18years of age

          -  Typical chest pain or objective evidence of myocardial ischemia suitable for elective
             PCI

          -  Significant coronary artery lesions suitable for DES(drug-eluting stent) implantation

          -  The patient or guardian agrees to the study protocol and the schedule of clinical
             follow-up, and provides informed, written consent, as approved by the appropriate
             Institutional Review Board/Ethical Committee of the respective clinical site.

        Exclusion Criteria:

          -  Angiographic exclusion criteria: any of the followings

               1. Bypass graft lesions

               2. Impaired delivery of IVUS is expected:

                    -  Extreme angulation (≥90°) proximal to or within the target lesion.

                    -  Excessive tortuosity (≥ two 45° angles) proximal to or within the target
                       lesion.

                    -  Heavy calcification proximal to or within the target lesion.

          -  Previous percutaneous coronary intervention within 6 months before the index
             procedure

          -  Previous BVS (bioresorbable vascular scaffold) implantation

          -  Left ventricular ejection fraction (LVEF) &lt; 30%

          -  Hypersensitivity or contraindication to device material and its degradants and
             cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
             be adequately pre-medicated.

          -  Persistent thrombocytopenia (platelet count &lt;100,000/µl)

          -  Any history of hemorrhagic stroke or intracranial hemorrhage, Transient ischemic
             attack or ischemic stroke within the past 6 months

          -  A known intolerance to a study drug (aspirin, clopidogrel or ticagrelor)

          -  Patients requiring long-term oral anticoagulants or cilostazol

          -  Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP
             antagonist is planned within 12 months after the procedure.

          -  A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in
             the past 3 years or current treatment for the active cancer.

          -  Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             Investigator, would preclude safe completion of the study.

          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (ALT or AST &gt; 3 times upper limit of normal).

          -  Life expectancy &lt; 1 years for any non-cardiac or cardiac causes

          -  Unwillingness or inability to comply with the procedures described in this protocol.

          -  Patient's pregnant or breast-feeding or child-bearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>November 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>professor, Division of Cardiology, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>IVUS guided PCI</keyword>
  <keyword>QCA guided PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
